- Home
- KTTA vs QLGN Comparison
KTTA vs QLGN Comparison
Compare KTTA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- QLGN
- Stock Information
- Founded
- KTTA 2020
- QLGN 1996
- Country
- KTTA United States
- QLGN United States
- Employees
- KTTA N/A
- QLGN N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- QLGN Health Care
- Exchange
- KTTA Nasdaq
- QLGN Nasdaq
- Market Cap
- KTTA 2.6M
- QLGN 2.4M
- IPO Year
- KTTA 2021
- QLGN N/A
- Fundamental
- Price
- KTTA $1.30
- QLGN $3.55
- Analyst Decision
- KTTA
- QLGN
- Analyst Count
- KTTA 0
- QLGN 0
- Target Price
- KTTA N/A
- QLGN N/A
- AVG Volume (30 Days)
- KTTA 3.3M
- QLGN 110.9K
- Earning Date
- KTTA 03-28-2025
- QLGN 04-07-2025
- Dividend Yield
- KTTA N/A
- QLGN N/A
- EPS Growth
- KTTA N/A
- QLGN N/A
- EPS
- KTTA N/A
- QLGN N/A
- Revenue
- KTTA N/A
- QLGN N/A
- Revenue This Year
- KTTA N/A
- QLGN N/A
- Revenue Next Year
- KTTA N/A
- QLGN N/A
- P/E Ratio
- KTTA N/A
- QLGN N/A
- Revenue Growth
- KTTA N/A
- QLGN N/A
- 52 Week Low
- KTTA $1.25
- QLGN $2.96
- 52 Week High
- KTTA $9.25
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- KTTA 30.34
- QLGN 47.06
- Support Level
- KTTA $1.32
- QLGN $3.16
- Resistance Level
- KTTA $1.38
- QLGN $3.75
- Average True Range (ATR)
- KTTA 0.26
- QLGN 0.21
- MACD
- KTTA -0.05
- QLGN 0.06
- Stochastic Oscillator
- KTTA 1.92
- QLGN 67.25
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.